Instructions for Credit — This activity is accredited for 1.75 continuing education credits for social workers. Participants must attend the free webinar in its entirety, submit the online evaluation form and complete and submit the online post-test with a passing score of 70% to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.
Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or firstname.lastname@example.org.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Social workers involved in the care of patients with hematopoietic stem cell transplantation (HCT).
Course Content Level for Social Workers — Intermediate and Advanced
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the types of hematopoietic cell transplantation used in the treatment of blood cancers, including autologous, allogeneic, and reduced-intensity allogeneic stem-cell transplantation|
|•||Identify the methods of stem-cell collection used in patients with blood cancers|
|•||Explain the overarching goals of hematopoietic cell transplantation for all types of blood cancers|
|•||Explain hematopoietic cell transplantation as a treatment option for blood cancers|
|•||Describe strategies to manage treatment side effects as well as potential long-term and late effects of hematopoietic cell transplantation|
|•||Describe the roles of the advanced practice provider, nurse, pharmacist, and the social worker in treating patients with HCT|
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Social Workers
Social Worker Designation
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/17-12/14/2020. Social workers completing this course receive 1.75 continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.75 CE clinical contact hours for this activity.
To view system requirements please go to https://llsce.org/system-requirements
For questions, grievances, or assistance with special needs (physical, etc.) please contact us at infocenter@LLS.org.
Disclosure of Conflicts of Interest — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Ran Reshef, MD, MSc, Consultant: Celgene, Gilead, Monsanto (Bayer), Novartis Pharmaceuticals.
Rachel Abramova, PharmD, has nothing to disclose.
Corinne Shamehdi, MPAS, PA-C, Consultant: Kite, A Gilead Company
Krista McCarthy, LCSW, has nothing to disclose.
Alison Hoffman, LMSW, has nothing to disclose.
Content/Peer Reviewer Disclosures
Elsa Delille, MSN, FNP-BC, has nothing to disclose.
Disclaimer –Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|Estimated time to complete activity: 1.75 hours|
|Date of initial release: August 25, 2020|
|Valid for CE credit through: August 25, 2021|
Ran Reshef, MD, MSc, is the Director of Translational Research in the Blood and Marrow Transplantation and Cell Therapy Program at Columbia University Medical Center. He is the clinical lead of the CAR-T cell program for both commercially available CAR-T and experimental cell therapies that are still in clinical trials. He directs a research lab in the Columbia Center for Translational Immunology and he is a member of the Herbert Irving Comprehensive Cancer Center.
Dr. Reshef’s research revolves around immunotherapy approaches for the treatment of cancer and his lab studies novel ways to improve the efficacy and the safety of immunotherapies including bone marrow transplants, checkpoint inhibitors and CAR-T cells. He has authored or co-authored more than 60 original research publications related to cancer and bone marrow transplantation and has received research funding from the Leukemia & Lymphoma Society, National Cancer Institute, Conquer Cancer Foundation, Department of Defense, National Marrow Donor Program and the American Society of Hematology.
Rachel Abramova, PharmD, currently serve as the Clinical Pharmacy Manager for Stem Cell Transplant/Multiple Myeloma at New York Presbyterian/Columbia University Irving Medical Center in New York, NY. She graduated with her Doctorate in Pharmacy from St. John’s university and completed both her PGY1 Pharmacy Practice Residency and PGY2 Oncology Pharmacy Residency at NewYork-Presbyterian Hospital. In her PGY2 year she served as Chief Resident. Rachel work with the inpatient stem cell transplant/multiple myeloma team to ensure safe use of chemotherapy and assists in supportive care and management of their patient population.
Corinne Shamehdi, MPAS, PA-C, holds a Master of Physician Assistant Studies degree from the University of Florida. Corinne is an Advanced Physician Assistant and the Cellular Therapy Lead for the inpatient Blood and Marrow Transplant Program at New York Presbyterian/Columbia University Irving Medical Center in New York, NY.
Krista McCarthy, LCSW, is a licensed clinical social worker covering all outpatient hematology oncology divisions– multiple myeloma, leukemia, lymphoma, the blood and marrow transplant and cellular therapy services- of New York Presbyterian. She began her NYP career in 2017, initially filling the role of outpatient BMT and myeloma social worker. The following year her practice grew to include the remaining hematology oncology service lines.
Ms. McCarthy earned her MSW from Touro College (NYC) ten years ago. Her career to this point has been exclusive to the medical field with past positions in pediatric critical care, dialysis and radiation oncology. She holds SIFI certification and enjoys supervising MSW students. She has also completed post-graduate certification training in trauma therapy, meaning centered psychotherapy and is an NYP Palliative Care Champion as well as a member of the Association of Oncology Social Work.
Alison Hoffman, LMSW, works as an Inpatient Hematology Oncology and BMT program Social Worker at NewYork-Presbyterian Hospital, Columbia University Irving Medical Center in New York, NY. Alison has been working with hematology/oncology patients on the bone marrow transplant unit since 2016.
Alison graduated from Rutgers University with a B.A. in Journalism and Media Studies and from Monmouth University with an Master of Social Work. Alison has been able to apply her journalism background to working with patients and their families and learning about the unique needs that impact the BMT population. Alison is a member of the Association of Oncology Social Work and has previously presented at their annual conference on the needs of post-transplant survivors. Alison is also an NYP Palliative Care Champion and is on the Social Work Board at the Bone Marrow and Cancer Foundation.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Treating Blood Cancers podcasts: www.LLS.org/HCPpodcast
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
HCT Specific Resources – www.LLS.org/HCT
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team.
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists